Palonosetron as an anti-emetic and anti-nausea agent in oncology

Therapeutics and Clinical Risk Management

Volumn 3, Issue 6, 2007, Pages 1009-1020

  Aapro, Matti S ^a  

^a CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

5 HT3 receptor antagonists; CINV; Highly emetogenic chemotherapy (HEC); Moderately emetogenic chemotherapy (MEC); Palonosetron

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APREPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PALONOSETRON; PALOXI; SEROTONIN 3 ANTAGONIST; STEROID; TROPISETRON; UNCLASSIFIED DRUG;

ALOPECIA; BINDING AFFINITY; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DISEASE CONTROL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; HUMAN; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; PATIENT COMPLIANCE; QT PROLONGATION; REVIEW; SINGLE DRUG DOSE; TASTE DISORDER; UNSPECIFIED SIDE EFFECT;

EID: 38049126428     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Aapro MS, Grunberg SM, Manikhas GM, et al. 2006. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol, 17:1441-9.
2. Aapro MS, Macciocchi A, Gridelli C. 2005. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients: Results from two randomized, controlled clinical trials. J Support Oncol, 3:369-74. Erratum in: J Support Oncol, 4:107 (2006).
3. Aloxi® (palonosetron HCl) prescribing information. 2003/2005. Bloomington, MN, USA: MGI PHARMA, INC.: (2003); Damastown, Dublin, Republic of Ireland: Helsinn Birex Pharmaceuticals Ltd. (2005).
4. Anzemet (dolasetron mesylate injection) prescribing information. 2003. Aventis Pharmaceuticals Inc, Kansas City, MO.
5. Bissoli F, McGuiggan M, Bertazzoli M, Post-marketing experience of palonosetron confirms a favourable benefit/risk profile. 2005. Support Care Cancer, 13:413, A04-17.
6. 3 antagonist, does not alter the antitumor efficacy of various chemotherapeutics in tumor bearing rodents. Clin Cancer Res, 9:6254s, AC207.
7. Coates A, Abraham S, Kaye SB, et al. 1983. On the receiving end: Patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol, 19:203-8.
8. 3 antagonists. Br J Cancer, 76:1055-61.
9. De Moor C, Cohen P, Eisenberg PD, et al. 2003. Oncologists compliance with anti-emetic guidelines and outcomes of patients receiving emetogenic chemotherapy. Proc Am Soc Clin Oncol, 22:727.
10. de Moor C, Cunningham RS. 2005. Improving the functional status of patients with cancer by more effectively preventing chemotherapy-induced nausea and vomiting (CINV): a comparison of palonosetron (PALO) vs ondansetron (OND) or dolasetron (DOL). J Support Oncol, 3(5 Suppl 3):25-6, PA-12.
11. Decker GM, DeMeyer ES, Kisko DL. 2006. Measuring the maintenance of daily life activities using the Functional Living Index-Emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol, 4:35-41.
12. 3 receptor antagonist, in vivo. Br J Pharmacol, 114:860-6.
13. 3 receptor antagonist: Results of a phase III, single-dose trial versus dolasetron. Cancer, 98:2473-82.
14. Eisenberg P, MacKintosh FR, Ritch P, et al. 2004. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol, 15:330-7.
15. Eisenberg PD, Rubenstein EB, Cohen L, et al. 2003. Perceptions and satisfaction (S) of oncologists and oncology (RNs) nurses of antiemetic therapy (AET) for chemotherapy-induced nausea and vomiting (CINV) vs patient experiences after emetogenic chemotherapy (CT) in the US. Proc Am Soc Clin Oncol, 22:740, A2974.
16. Gralla R, Lichinitser M, Van der Vegt S, et al. 2003. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol, 14:1570-7.
17. 3-receptor antagonist antiemetics: focus on elderly cancer patients. Support Care Cancer, 12:487-96.
18. Griffin AM, Butow PN, Coates AS, et al. 1996. On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol, 7:189-95.
19. Grote T, Hajdenberg J, Cartmell A, et al. 2006. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol, 4:403-8.
20. Grunberg S, Vanden Burgt J, Berry S, et al. 2004. Prevention of delayed nausea and vomiting (D-CINV): Carryover effect analysis of pooled data from 2 phase III studies of palonosetron (PALO). J Clin Oncol, 22:A8051.
21. Grunberg SM, Deuson RR, Mavros P, et al. 2004. Incidence of chemotherapy-induced nausea and emesis after modem antiemetics. Cancer, 100:2261-8.
22. 3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother, 4:2297-303.
23. Grunberg SM, Zhang M, Zhang Q, et al. 2000. Hospital service use associated with chemotherapy-induced emesis and nausea for patients with principal or secondary diagnosis of cancer. Eur J Cancer, 36(Suppl 3):S28. Abstract #71.
24. Hajdenberg J, Grote T, Yee L, et al. 2006. Infusion of Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. J Support Oncol, 4:467-71.
25. Hesketh P, Navari R, Grote T, et al. 1996. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron methylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy- Induced Emesis Prevention Group. J Clin Oncol, 14:2242-9.
26. Hesketh PJ, Kris MG, Grunberg SM, et al. 1997. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol, 15:103-9.
27. Hesketh PJ, Van Belle S, Aapro M, et al. 2003. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer, 39:1074-80.
28. 3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest, 18:163-73.
29. Hornby PJ. 2001. Central neurocircuitry associated with emesis. Am J Med, 111(Suppl 8A):106S-112S.
30. Koeller JM, Aapro MS, Gralla RJ, et al. 2002. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer, 10:519-22.
31. Lindley C, McCune JS, Thomason TE, et al. 1999. Perception of chemotherapy side effects: cancer versus non-cancer patients. Cancer Pract, 7:59-65.
32. Navoban (tropisetron hydrochloride) prescribing information. 2001. Novartis New Zealand Limited, Avondale, Auckland, New Zealand.
33. Roila F, Hesketh PJ, Herrstedt J. 2006. Antiemetic Subcommitte of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol, 17:20-8.
34. Rubenstein EB, Gralla RJ, Eisenberg P, et al. 2003. Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV): Combined results of two phase III trials. Proc Am Soc Clin Oncol, 22:729, A2932.
35. Stoltz R, Cyong J-C, Shah A, et al. 2004. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in US and Japanese healthy subjects. J Clin Pharmacol, 44:520-31.
36. Trissel LA, Xu QA. 2005. Physical and chemical stability of palonosetron hydrochloride with Topotecan Hydrochloride and Irinotecan Hydrochloride during simulated Y-site administration. Int J Pharm Comp, 9:238.
37. Trissel LA, Zhang Y. 2004a. Compatibility and stability of Aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate. Int J Pharmaceut Compound, 8:398-403.
38. Trissel LA, Zhang Y. 2004b. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin, and oxaliplatin during simulated Y-site administration. J Onc Pharm Pract, 10:191-5.
39. Trissel LA, Zhang Y. 2005a. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann Pharmacother, 39:280-3.
40. Trissel LA, Zhang Y. 2005b. Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. Int J Pharm Comp, 9:320-2.
41. Vardy J, Chiew KS, Galica J, et al. 2006. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer, 94:1011-15.
42. 3 receptors, in vitro. Br J Pharmacol, 114:851-9.
43. Xu QA, Trissel LA. 2004. Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration. Am J Health Syst Pharm, 61:1596-8.